Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29586069 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL15717047 | 0.98 | SLC6A2 (0.48) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL3702120 | 0.80 | MTNR1A (0.38) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL30274923 | 0.78 | NOTUM (0.43) | SLC6A2SLC6A4CYP2D6KCNH2ACHE | |
| SCHEMBL7673078 | 0.78 | NOTUM (0.43) | SLC6A2SLC6A4CYP2D6KCNH2ACHE | |
| SCHEMBL10173840 | 0.78 | NOTUM (0.43) | SLC6A2SLC6A4CYP2D6KCNH2ACHE | |
| SCHEMBL23346884 | 0.77 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL10246637 | 0.77 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL28239155 | 0.77 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL21950021 | 0.77 | ACHE (0.38) | SLC6A2SLC6A4CYP2D6KCNH2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-4463452-B1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-03 | — | — | US | disclosed |
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-3725787-B1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2023-11-02 | — | — | US | disclosed |
| WO-2023177700-A2 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-4240736-A1 | PPAR GAMMA MODULATORS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-8030504-B2 | Pain, especially, inflammatory hyperalgesia, ostheoarthritic pain, chronic lower pain, allodynia, migraine. Methods of controlling pain and treating bladder overactivity and urinary incontinence | ABBOTT LABORATORIES (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110136864-A1 | TETRAHYDROQUINOLINE INDOLE DERIVATIVES AND USES THEREOF | SCHOENFELD RYAN CRAIG | 2011-06-09 | — | — | US | disclosed |
| EP-2134678-A2 | N-(5, 6, 7, 8-TETRAHYDRONAPHTHALEN-1-YL) UREA DERIVATIVES AND RELATED COMPOUNDS AS TRPV1 VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | disclosed |
| CN-101429160-A | Synthesis of 1-R-4-amino-1,2,3,4-tetrahydroquinoline | SHANGHAI PHARMATECH CO LTD (CN) | 2009-05-13 | — | — | CN | disclosed |
| WO-2008079683-A2 | N- (5, 6, 7, 8-TETRAHYDRONAPHTHALEN-1-YL) UREA DERIVATIVES AND RELATED COMPOUNDS AS TRPV1 VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| US-7332509-B2 | Heterocyclic amides, a process for their preparation, compositions comprising them and their use | MERIAL LIMITED (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332509-B2 | Heterocyclic amides, a process for their preparation, compositions comprising them and their use | MERIAL LIMITED (US) | 2008-02-19 | — | — | US | disclosed |
| US-7186731-B2 | 2-cyanopyrrolidinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2007-03-06 | — | — | US | disclosed |
| US-20050137224-A1 | 2-Cyanopyrrolidinecarboxamide compound | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | SLC6A2 968/4885SLC6A3 623/4885SLC6A4 701/4885 |
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | SLC6A2 4420/4885SLC6A3 4454/4885SLC6A4 4205/4885 |
| US-20050137224-A1 | 2-Cyanopyrrolidinecarboxamide compound | DPP4, DPP3, DPP7 | SLC6A2 575/4885SLC6A3 408/4885SLC6A4 598/4885 |
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | SLC6A2 4854/4885SLC6A3 4667/4885SLC6A4 4832/4885 |
| US-20110136864-A1 | TETRAHYDROQUINOLINE INDOLE DERIVATIVES AND USES THEREOF | IDO1, IDO2, TPH1 | SLC6A2 242/4885SLC6A3 244/4885SLC6A4 147/4885 |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | SLC6A2 4690/4885SLC6A3 4564/4885SLC6A4 4645/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | SLC6A2 2968/4885SLC6A3 3196/4885SLC6A4 1855/4885 |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | SLC6A2 4690/4885SLC6A3 4564/4885SLC6A4 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.